TUESDAY, Nov. 22 (HealthDay News) -- British researchers have
good news for anyone taking the cholesterol-lowering medications
known as statins: These drugs are effective and safe, even when
used for long periods of time, they say.
The 11-year study found that simvastatin (brand name Zocor)
reduced the risk of cardiovascular disease by almost one-quarter.
In addition, the researchers found no increase in illness or deaths
from cancer or other non-vascular causes.
"All those at increased vascular risk should start taking statins early and continue taking them long term," said the study's lead author, Dr. Richard Bulbulia, a consultant vascular surgeon and research fellow in the clinical trial service unit at the University of Oxford in England.
"This will maximize the reductions in heart attacks, strokes and other vascular diseases, and is safe," said Bulbulia, who added that the study's findings should provide reassurance to physicians and their patients.
There are numerous other drugs in this class of medication, and
Bulbulia said, "it seems reasonable to assume that [this study's
findings] should hold true for other currently prescribed statins."
Other commonly used statins include Lipitor, Crestor and
Results of the study are published in the Nov. 23 online issue
The Lancet. Funding for the study was provided by the U.K. Medical Research Council, the British Heart Foundation, Merck & Co. (manufacturer of Zocor) and Roche Vitamins.
The study looked at the long-term safety of simvastatin because
some research suggested that the rates of some cancers and
non-vascular health conditions were increased in people who had
lower levels of LDL (bad) cholesterol.
Initially, the study recruited more than 20,500 people who had a
high risk of heart disease and other cardiovascular problems for a
trial of simvastatin versus a placebo. The study volunteers were
between 40 and 80 years old.
Half the group was randomly assigned to take 40 milligrams of
simvastatin daily, while the other half took a placebo. At the end
of the treatment phase of the trial, which lasted about five years,
study participants were encouraged to continue on their study
treatment for as long as another six years. About 17,500 of the
initial participants continued in the follow-up phase, according to
People taking simvastatin reduced their "bad" cholesterol an
average of 1 millimole per liter over five years. This reduction
translated into a 23 percent drop in the risk of major
cardiovascular events, such as heart attack and stroke, the
researchers said. This benefit continued throughout the follow-up,
reported the study.
When the researchers examined the data from the treatment and
follow-up phases for evidence of any increases in non-vascular
events, such as cancer, they found no significant differences
between the two groups.
"Statin therapy appears safe, with no hazards, such as an excess risk of cancer or other major non-vascular morbidity or mortality emerging during the 11-year post-trial period," said Bulbulia.
Another expert praised statins' record.
"I think the statin drugs are an extraordinary class of medications, and a necessity in Western populations, where there is less physical exercise and more calorie consumption," said Dr. Howard Weintraub, clinical director of the Center for the Prevention of Cardiovascular Disease at NYU Langone Medical Center in New York City.
"These are very safe drugs, and this study demonstrates that safety, and that the vascular protection continues well beyond the termination of treatment," said Weintraub.
"I think the picture for cardiovascular disease would be very different if these drugs weren't a part of our armamentarium," he added.
Learn more about statins from the
U.S. Food and Drug Administration.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.